BIONEWS
FDA's 'breakthrough' designation covers devices for life threatening conditions; Medicare usually takes years to start paying.
On August 11, 2026, CMS published a procedural notice, CMS-3487-NC, opening a public comment period on a new mechanism called RAPID, the Regulatory Alignment for Predictable and Immediate Device Coverage Pathway. The Federal Register version is document 2026-16368. The same day, CMS and FDA put out a joint press release framing RAPID as the missing bridge across what the industry calls the device "valley of death."
"Breakthrough device" is a specific FDA designation, not a marketing term. It is reserved for devices that could treat or diagnose an irreversible or life-threatening condition, where no cleared alternative exists, and where the device shows early signs of substantial improvement. Once a device earns that label, FDA's press announcement on the pathway makes the policy intent explicit: get Medicare to start paying for it close to the moment FDA clears it, not years later.
Until now, the FDA-to-Medicare sequence has worked in two stages with a long pause between them. A device earns breakthrough status, runs its clinical trials, gets cleared or approved, and then waits while CMS opens a separate national coverage determination, drafts a billing code, and prices the device. The STAT+ newsletter introducing the notice described it as a mechanism "to help medical devices escape the valley of death," the industry shorthand for that waiting stretch, where clearance without payment leaves a cleared device sitting on a shelf and its manufacturer running out of runway before reimbursement arrives.
RAPID is the agencies' answer to that gap. The mechanism is procedural, not statutory, and the Aug. 11 notice is the start of a comment period, not a final rule. If adopted, the pathway would let CMS start preparing coverage, coding, and payment rules in parallel with FDA's later-stage review of a breakthrough device, instead of after it. The joint press release frames the goal as giving Medicare patients faster access to devices that have already cleared the breakthrough bar.
The mechanism changes who has to react first. Under RAPID, the manufacturer and CMS would be on the clock at the same time, with CMS signaling earlier which patient populations and evidence it expects to see. That shifts leverage on three groups: device makers gain a more predictable reimbursement runway, investors gain a shorter path to revenue, and CMS gains earlier visibility into which technologies it is about to pay for.
That is the same shift frontline nurses described in a separate STAT+ story the same day. The newsletter introduced the piece as a frontline view of how AI is already moving into clinical workflows, and the nurses' coalition's ask was direct: a formal seat at the table where clinical AI is selected, deployed, and evaluated at the bedside. The story is not a referendum on AI as a category. It is a warning that the same institutional urgency that lets Medicare pay for breakthrough devices faster is the urgency nurses say is already pushing AI tools into clinical use ahead of the oversight those tools need.
The two threads sit on the same fault line. RAPID is a federal attempt to align two agencies that historically work in sequence, so a device cleared by FDA does not stall at CMS. The nurses' coalition is asking the healthcare system to do a similar alignment between clinical innovation and clinical governance, so a tool that arrives at the bedside is not arriving alone. The federal mechanism is procedural and open for comment. The clinical question is whether the system that pays for a device faster can also watch the way it is used.
The comment period on CMS-3487-NC is now open.